[Polypodiaceae], Foreknowledge) In a randomized controlled trial of 44 patients with advanced prostate cancer (APC), YJQR treatment with endocrine therapy for 6 months increased prostate specific antigen (PSA), free PSA (f-PSA) and hemoglobin (Hb) in serum. Here, KLK3 is linked to prostate carcinoma.